RxDoctor Payments Data

Peter Tek, DO

Urology · Joliet, ILNPI 1235403130

Payments from drug & device makers

$6,765in general payments, 2019–2025

Across 319 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Coloplast$629
  • AbbVie$329
  • Antares Pharma, Inc.$310
  • Boston Scientific$301
  • Bayer$289
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$5,97788%
  • Education$72511%
  • Other$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,765 in reported general payments places this provider in the 70th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$582,088
Medicare patients
1,306
Services billed
18,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide11$169,508
MyrbetriqMirabegron127$96,681
GemtesaVibegron50$34,847
ElmironPentosan Polysulfate Sodium11$18,494
Solifenacin Succinate343$17,606
Tamsulosin Hcl1,205$16,065
XyostedTestosterone Enanthate21$12,291
Mirabegron ErMirabegron18$9,242
Silodosin133$8,386
Finasteride410$5,292
Trospium Chloride ErTrospium Chloride52$5,027
Fosfomycin Tromethamine18$4,042
Oxybutynin Chloride ErOxybutynin Chloride140$3,215
Cephalexin332$2,733
Estradiol48$2,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$256$169,50811 claims
Astellas Pharma US IncMyrbetriq$1,333$96,681127 claims
Sumitomo Pharma America, Inc.Gemtesa$74$34,84750 claims
Antares Pharma, Inc.Xyosted$310$12,29121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 550 urology providers in Illinois.

Other urology in Joliet

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →